Despite the COVID-19 pandemic, Q220 brought in unexpected strong demand for orthopedic robotics. Companies rose to the challenge through flexible business models to accommodate limitations in short-term hospital financial constraints through increased financing and implant volume commitments. The unexpected strength in robotics revenues also demonstrated a rebound in elective (total joint) procedures that is expected to normalize in early 2021.
Among the many topics covered in the comprehensive Q220 CAS Ortho Market Recap* are:
Companies across the board are also positioning their enabling technologies for use in ASCs as the shift of orthopedic procedures from hospitals to outpatient/ASC settings is anticipated to accelerate as a result of ...
*The entire article and the links can only be viewed by SmartTRAK subscribers to this module. For more information on how to receive a demo and subscribe, please click the button below.